title: [Prevention of bone loss in a patient receiving androgen deprivation therapy].
abstract: Bone loss is a frequent side effect of androgen deprivation therapy, which leads to a significant number of pathologic fractures. Prevention of osteoporosis aims at reducing skeletal-related events. The RANK ligand antibody denosumab and bisphosphonates are used for this indication. Denosumab has been shown to increase bone density and to reduce the incidence of fractures at any location by 72%. Bone density can also be increased by bisphosphonates; however, there is no conclusive evidence so far that the fracture rate can be reduced significantly. Therefore guidelines do not recommend use of these substances for this indication.
authors.affiliation: Abteilung für Urologie, Kinderurologie und Uro-Onkologie, St. Josef-Hospital Troisdorf, Hospitalstraße 45, Troisdorf, Germany. norbert.rolfes@josef-hospital.de
authors.forename: N
authors.initials: N
authors.lastname: Rolfes
authors.forename: G
authors.initials: G
authors.lastname: Lümmen
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005598:Fractures, Spontaneous / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents